FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211928898> ?p ?o ?g. }

• W3211928898 endingPage "5607" @default.
• W3211928898 startingPage "5607" @default.
• W3211928898 abstract "Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph-) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL; n = 267) and Ph+ BCP-ALL (n = 45) from the TOWER and ALCANTARA studies, respectively, or chemotherapy in patients with Ph- BCP-ALL (n = 109) from the TOWER study; all the patients with relapsed/refractory BCP-ALL and responders achieving complete remission (CR) or CR with partial/incomplete hematological recovery (CRh/CRi) were evaluated. Event-free survival (EFS) and overall survival (OS) were assessed in patients achieving CR and CRh/CRi. Median leukocyte, neutrophil, and platelet counts increased during two blinatumomab cycles but remained low longer after chemotherapy. Among the responders, there was a trend that a greater proportion of patients achieved CR with blinatumomab (Ph-, 76.5%; Ph+, 77.8%) versus with chemotherapy (Ph-, 63.6%). In the TOWER study, the survival prognosis for patients achieving CRh/CRi versus CR with blinatumomab was more similar (median OS, 11.9 (95% CI, 3.9-not estimable (NE)) vs. 15.0 (95% CI, 10.4-NE) months, p = 0.062) than with chemotherapy (5.2 (95% CI, 1.6-NE) vs. 18.9 (95% CI, 9.3-NE) months, p = 0.013). Blinatumomab treatment, with only temporary and transient myelosuppression, resulted in a greater survival benefit than chemotherapy." @default.
• W3211928898 created "2021-11-22" @default.
• W3211928898 creator A5013754928 @default.
• W3211928898 creator A5024202047 @default.
• W3211928898 creator A5035397993 @default.
• W3211928898 creator A5037133740 @default.
• W3211928898 creator A5073761054 @default.
• W3211928898 creator A5075073484 @default.
• W3211928898 creator A5090435894 @default.
• W3211928898 date "2021-11-09" @default.
• W3211928898 modified "2023-09-26" @default.
• W3211928898 title "Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia" @default.
• W3211928898 cites W1488000644 @default.
• W3211928898 cites W1511187821 @default.
• W3211928898 cites W1546909751 @default.
• W3211928898 cites W1974020263 @default.
• W3211928898 cites W1991644988 @default.
• W3211928898 cites W1996815863 @default.
• W3211928898 cites W2006464326 @default.
• W3211928898 cites W2015956932 @default.
• W3211928898 cites W2038139667 @default.
• W3211928898 cites W2055373109 @default.
• W3211928898 cites W2070520252 @default.
• W3211928898 cites W2080669705 @default.
• W3211928898 cites W2081255800 @default.
• W3211928898 cites W2136453261 @default.
• W3211928898 cites W2141541834 @default.
• W3211928898 cites W2177293834 @default.
• W3211928898 cites W2419639370 @default.
• W3211928898 cites W2563060241 @default.
• W3211928898 cites W2591709377 @default.
• W3211928898 cites W2599899418 @default.
• W3211928898 cites W2615844508 @default.
• W3211928898 cites W2772481439 @default.
• W3211928898 cites W2782994300 @default.
• W3211928898 cites W2787145330 @default.
• W3211928898 cites W2913371460 @default.
• W3211928898 cites W2990115538 @default.
• W3211928898 cites W3006232173 @default.
• W3211928898 cites W3022796443 @default.
• W3211928898 cites W3026558549 @default.
• W3211928898 cites W3037830886 @default.
• W3211928898 cites W3043131535 @default.
• W3211928898 cites W3044836741 @default.
• W3211928898 cites W3086049345 @default.
• W3211928898 cites W3091950740 @default.
• W3211928898 cites W3115281787 @default.
• W3211928898 cites W3115793324 @default.
• W3211928898 cites W3126591541 @default.
• W3211928898 cites W3128918508 @default.
• W3211928898 cites W3134763925 @default.
• W3211928898 cites W3135688349 @default.
• W3211928898 cites W3164356080 @default.
• W3211928898 cites W3184676053 @default.
• W3211928898 cites W4323517880 @default.
• W3211928898 doi "https://doi.org/10.3390/cancers13225607" @default.
• W3211928898 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8616108" @default.
• W3211928898 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34830762" @default.
• W3211928898 hasPublicationYear "2021" @default.
• W3211928898 type Work @default.
• W3211928898 sameAs 3211928898 @default.
• W3211928898 citedByCount "3" @default.
• W3211928898 countsByYear W32119288982022 @default.
• W3211928898 countsByYear W32119288982023 @default.
• W3211928898 crossrefType "journal-article" @default.
• W3211928898 hasAuthorship W3211928898A5013754928 @default.
• W3211928898 hasAuthorship W3211928898A5024202047 @default.
• W3211928898 hasAuthorship W3211928898A5035397993 @default.
• W3211928898 hasAuthorship W3211928898A5037133740 @default.
• W3211928898 hasAuthorship W3211928898A5073761054 @default.
• W3211928898 hasAuthorship W3211928898A5075073484 @default.
• W3211928898 hasAuthorship W3211928898A5090435894 @default.
• W3211928898 hasBestOaLocation W32119288981 @default.
• W3211928898 hasConcept C126322002 @default.
• W3211928898 hasConcept C142424586 @default.
• W3211928898 hasConcept C2776694085 @default.
• W3211928898 hasConcept C2778020697 @default.
• W3211928898 hasConcept C2778461978 @default.
• W3211928898 hasConcept C2780007613 @default.
• W3211928898 hasConcept C2781107101 @default.
• W3211928898 hasConcept C2909962599 @default.
• W3211928898 hasConcept C71924100 @default.
• W3211928898 hasConcept C86803240 @default.
• W3211928898 hasConcept C87355193 @default.
• W3211928898 hasConcept C90924648 @default.
• W3211928898 hasConceptScore W3211928898C126322002 @default.
• W3211928898 hasConceptScore W3211928898C142424586 @default.
• W3211928898 hasConceptScore W3211928898C2776694085 @default.
• W3211928898 hasConceptScore W3211928898C2778020697 @default.
• W3211928898 hasConceptScore W3211928898C2778461978 @default.
• W3211928898 hasConceptScore W3211928898C2780007613 @default.
• W3211928898 hasConceptScore W3211928898C2781107101 @default.
• W3211928898 hasConceptScore W3211928898C2909962599 @default.
• W3211928898 hasConceptScore W3211928898C71924100 @default.
• W3211928898 hasConceptScore W3211928898C86803240 @default.
• W3211928898 hasConceptScore W3211928898C87355193 @default.
• W3211928898 hasConceptScore W3211928898C90924648 @default.
• W3211928898 hasFunder F4320307105 @default.

• next